Silo Pharma, Inc. (SILO)
| Market Cap | 4.01M -39.3% |
| Revenue (ttm) | 54,077 |
| Net Income | -4.47M |
| EPS | -5.07 |
| Shares Out | 1.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,971 |
| Open | 3.250 |
| Previous Close | 3.220 |
| Day's Range | 3.090 - 3.340 |
| 52-Week Range | 2.750 - 15.150 |
| Beta | 0.80 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2026 |
About SILO
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a ... [Read more]
Financial Performance
In 2025, Silo Pharma's revenue was $72,102, a change of 0.00% compared to the previous year's $72,102. Losses were -$4.23 million, -3.76% less than in 2024.
Financial StatementsNews
Silo Pharma granted European patent covering PTSD therapy
Silo Pharma (SILO) announced that the European Patent Office has granted a patent covering the preventative approach of its lead candidate SPC-15, a novel intranasal, nose-to-brain treatment targeting...
Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform
Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption
Silo Pharma files to sell 1.91M shares of common stock for holders
16:07 EDT Silo Pharma (SILO) files to sell 1.91M shares of common stock for holders
Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program
Silo continues to add technology assets as it expands its AI business and further develops its lead PTSD therapeutic candidate
Silo Pharma subsidiary QwikAgents joins AMD AI program
Silo Pharma (SILO) announced that its wholly owned subsidiary, QwikAgents, has been accepted into the Advanced Micro Devices’ (AMD) artificial intelligence developer program. Participation in the prog...
Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agents Access to AMD Developer Cloud credits, AI development tools and tech...
Silo Pharma prices $11.7M at-the-market offering at $6.45 per share
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$4 million upfront with up to approximately $7.7 million of potential additional gross proceeds upon the exercise in full of warrants in cash
Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program
NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing
Silo Pharma engages Resyca to conduct a robustness study for SPC-15 delivery
Silo Pharma (SILO) announced that it has engaged its drug-device development partner Resyca to conduct a robustness study evaluating the microchip-based nasal spray system used for nose-to-brain deliv...
Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system
Silo Pharma reports positive stability data for stress treatment SPC-15
Silo Pharma (SILO) announced positive physical, chemical, and microbiological stability data for its investigational intranasal candidate, SPC-15, through nine months of real-time testing. The testing...
Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA., June 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo...
Silo Pharma regains compliance with Nasdaq min bid price requirement
Silo Pharma (SILO) announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market informing the Company that, as of June 17, 2026, it has regained…
Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
SARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery ...
Silo Pharma Inc trading halted, news pending
19:50 EDT Silo Pharma (SILO) Inc trading halted, news pending
Silo Pharma files provisional patent for ibogaine-based therapeutics
Silo Pharma (SILO) announced a strategic initiative to explore ibogaine-based therapeutics for the treatment of traumatic brain injury and associated neuropsychiatric conditions. Silo has filed a prov...
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines
Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment
Silo Pharma expands into AI technology with Qwikagents asset purchase
Silo Pharma (SILO) announced a strategic business expansion into AI technology as a second line of business resulting from its recent purchase of the assets of Qwikagents.ai, an AI platform…
Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1 SARASOTA, FL, April 22, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO...
Silo Pharma gets European Patent Office allowance for PTSD prevention therapy
Silo Pharma (SILO) announced that the European Patent Office has issued a Rule 71 communication indicating its intent to grant a patent for an European patent application titled “Prophylactic Efficacy...
Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy
EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio SARASOTA, FL, April 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SIL...
Silo Pharma announces $1M share repurchase program
Silo Pharma (SILO) announced that its board of directors has authorized a share repurchase program to acquire up to $1M of the company’s common stock. The company may purchase common…
Silo Pharma Announces Share Buyback Program
Sarasota, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psych...